论文部分内容阅读
一种新的头霉素——双硫唑甲氧头孢菌素(cefotetan)与噻吩甲氧头孢菌素、呋肟头孢菌素、羟羧氧酰胺菌素、噻甲羧肟头孢菌素以及氧哌嗪青霉素比较了它们对最近临床分离的273菌株的体外活性。双硫唑甲氧头孢菌素对90%的肠杆菌,流感嗜血杆菌、淋球菌的最低抑菌浓度是0.12～2μg/ml,而对90%的金黄色葡萄球菌的最低抑菌浓度是8μg/ml;对90%的脆弱拟杆菌、绿脓杆菌及兰斯菲耳德D链球菌的最低抑菌浓度是128μg/ml,或更高些。本品抗肠杆菌的活性与噻甲羧肟头孢菌素的羟羧氧酰胺菌素相同,而比噻吩甲氧头孢菌素和呋肟头孢菌素
A novel cefotetan-cefotetan with thiophene methoxy cephalosporins, furosemide cephalosporins, oxycarboxam, cefotaxime and cefotaxime Piperazine penicillin compared their in vitro activity against the recently clinically isolated 273 strain. The minimum inhibitory concentration of bisthiazolyl cephalosporin against 90% of Enterobacteriaceae, Haemophilus influenzae and Neisseria gonorrhoeae is 0.12 ~ 2μg / ml, while the minimum inhibitory concentration of 90% of Staphylococcus aureus is 8μg / ml; The minimum inhibitory concentration of 90% Bacteroides fragilis, Pseudomonas aeruginosa and Lansford streptococcus is 128 μg / ml or more. This product against Enterobacteriaceae activity and thiaclacri such as hydroxycarboxamide cephalosporin hydroxycarboxamide the same, and more than thiophene methoxy cephalosporins and furosemide cephalosporin